204 related articles for article (PubMed ID: 31150422)
1. Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy.
Sakurai A; Ono H; Ochi A; Matsuura M; Yoshimoto S; Kishi S; Murakami T; Tominaga T; Nagai K; Abe H; Doi T
PLoS One; 2019; 14(5):e0216788. PubMed ID: 31150422
[TBL] [Abstract][Full Text] [Related]
2. Urinary Exosomal mRNA of WT1 as Diagnostic and Prognostic Biomarker for Diabetic Nephropathy.
Abe H; Sakurai A; Ono H; Hayashi S; Yoshimoto S; Ochi A; Ueda S; Nishimura K; Shibata E; Tamaki M; Kishi F; Kishi S; Murakami T; Nagai K; Doi T
J Med Invest; 2018; 65(3.4):208-215. PubMed ID: 30282862
[TBL] [Abstract][Full Text] [Related]
3. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis.
Zubiri I; Posada-Ayala M; Sanz-Maroto A; Calvo E; Martin-Lorenzo M; Gonzalez-Calero L; de la Cuesta F; Lopez JA; Fernandez-Fernandez B; Ortiz A; Vivanco F; Alvarez-Llamas G
J Proteomics; 2014 Jan; 96():92-102. PubMed ID: 24211404
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo.
Du M; Wang Q; Li W; Ma X; Wu L; Guo F; Zhao S; Huang F; Wang H; Qin G
Biochem Biophys Res Commun; 2016 Mar; 471(4):416-22. PubMed ID: 26902117
[TBL] [Abstract][Full Text] [Related]
5. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte.
Duan YR; Chen BP; Chen F; Yang SX; Zhu CY; Ma YL; Li Y; Shi J
J Cell Mol Med; 2021 Dec; 25(23):10798-10813. PubMed ID: 31568645
[TBL] [Abstract][Full Text] [Related]
6. Hypertrophy and loss of podocytes in diabetic nephropathy.
Miyauchi M; Toyoda M; Kobayashi K; Abe M; Kobayashi T; Kato M; Yamamoto N; Kimura M; Umezono T; Suzuki D
Intern Med; 2009; 48(18):1615-20. PubMed ID: 19755763
[TBL] [Abstract][Full Text] [Related]
7. Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte.
Jin J; Shi Y; Gong J; Zhao L; Li Y; He Q; Huang H
Stem Cell Res Ther; 2019 Mar; 10(1):95. PubMed ID: 30876481
[TBL] [Abstract][Full Text] [Related]
8. An adjustment in BMP4 function represents a treatment for diabetic nephropathy and podocyte injury.
Fujita Y; Tominaga T; Abe H; Kangawa Y; Fukushima N; Ueda O; Jishage KI; Kishi S; Murakami T; Saga Y; Kanwar YS; Nagai K; Doi T
Sci Rep; 2018 Aug; 8(1):13011. PubMed ID: 30158674
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory smads and tgf-Beta signaling in glomerular cells.
Schiffer M; Schiffer LE; Gupta A; Shaw AS; Roberts IS; Mundel P; Böttinger EP
J Am Soc Nephrol; 2002 Nov; 13(11):2657-66. PubMed ID: 12397035
[TBL] [Abstract][Full Text] [Related]
10. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
11. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
12. Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes.
Wu X; Gao Y; Xu L; Dang W; Yan H; Zou D; Zhu Z; Luo L; Tian N; Wang X; Tong Y; Han Z
Sci Rep; 2017 Aug; 7(1):9371. PubMed ID: 28839221
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of TLR4 attenuates high glucose-induced podocyte injury via the NALP3/ASC/Caspase-1 signaling pathway.
Liu Y; Xu Z; Ma F; Jia Y; Wang G
Biomed Pharmacother; 2018 Nov; 107():1393-1401. PubMed ID: 30257355
[TBL] [Abstract][Full Text] [Related]
14. Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria.
Kalani A; Mohan A; Godbole MM; Bhatia E; Gupta A; Sharma RK; Tiwari S
PLoS One; 2013; 8(3):e60177. PubMed ID: 23544132
[TBL] [Abstract][Full Text] [Related]
15. Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes.
Lioudaki E; Stylianou KG; Petrakis I; Kokologiannakis G; Passam A; Mikhailidis DP; Daphnis EK; Ganotakis ES
Nephron; 2015; 131(1):34-42. PubMed ID: 26340089
[TBL] [Abstract][Full Text] [Related]
16. Swiprosin-1 Promotes Mitochondria-Dependent Apoptosis of Glomerular Podocytes via P38 MAPK Pathway in Early-Stage Diabetic Nephropathy.
Wang RM; Wang ZB; Wang Y; Liu WY; Li Y; Tong LC; Zhang S; Su DF; Cao YB; Li L; Zhang LC
Cell Physiol Biochem; 2018; 45(3):899-916. PubMed ID: 29421811
[TBL] [Abstract][Full Text] [Related]
17. Glomerular podocytes in diabetic renal disease.
Podgórski P; Konieczny A; Lis Ł; Witkiewicz W; Hruby Z
Adv Clin Exp Med; 2019 Dec; 28(12):1711-1715. PubMed ID: 31851794
[TBL] [Abstract][Full Text] [Related]
18. Activated YAP causes renal damage of type 2 diabetic nephropathy.
Ma R; Ren JM; Li P; Zhou YJ; Zhou MK; Hu Z; Xiao XY
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):755-763. PubMed ID: 30720184
[TBL] [Abstract][Full Text] [Related]
19. PRMT1 mediates podocyte injury and glomerular fibrosis through phosphorylation of ERK pathway.
Zhu Y
Biochem Biophys Res Commun; 2018 Jan; 495(1):828-838. PubMed ID: 29129692
[TBL] [Abstract][Full Text] [Related]
20. [Change and significance of urinary smad3 in type 2 diabetic nephropathy].
Guo KF; Kou JX; Lu JX; Zhang L; Yu HY; Chen HB
Zhonghua Yi Xue Za Zhi; 2013 Apr; 93(14):1067-71. PubMed ID: 23902838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
